Last reviewed · How we verify
Symbicort pMDI with spacer device
At a glance
| Generic name | Symbicort pMDI with spacer device |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus) (PHASE4)
- A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers (PHASE1)
- Phase IV O2 Consumption Study in COPD Patients. (PHASE4)
- Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Symbicort pMDI with spacer device CI brief — competitive landscape report
- Symbicort pMDI with spacer device updates RSS · CI watch RSS
- AstraZeneca portfolio CI